奥美沙坦酯联合苯磺酸氨氯地平对血液透析患者的治疗作用  

Effects of olmesartan medoxomil combined with amlodipine besylate on hemodialysis patients

作　　者：王楠楠[1] 冯锦红[1] 柳彩侠[1] 孙东[1,2,3] 

机构地区：[1]徐州医学院附属医院肾内科,江苏徐州221002 [2]伊犁哈萨克自治州奎屯医院消肾内科,新疆奎屯833200 [3]徐州医学院内科学与诊断学教研室,江苏徐州221002

出　　处：《徐州医学院学报》2014年第5期312-315,共4页Acta Academiae Medicinae Xuzhou

基　　金：基金项目：国家自然科学基金（81270769）;江苏省医学重点人才项目（RC2011116）;江苏省第七批“六大人才高峰”资助项目（2010-ws043）;新疆伊犁哈萨克自治州奎屯市课题（201134）

摘　　要：目的：探讨奥美沙坦酯联合苯磺酸氨氯地平对维持性血液透析（ MHD）高血压患者血压和微炎症状态的影响。方法80例MHD高血压患者应用随机数字表法随机分为对照组和治疗组（每组40例），对照组患者给予苯磺酸氨氯地平口服，治疗组患者给予奥美沙坦酯联合苯磺酸氨氯地平口服，疗程均为8周。观察2组治疗前后血压及高敏C反应蛋白（ hs-CRP）、α1-酸性糖蛋白（α1-AAG）水平变化。同时设40例健康对照组。结果治疗组总有效率为90．5％，明显高于对照组的67．5％（P＜0．05），2组治疗后收缩压和舒张压均较治疗前明显下降（P＜0．05），但治疗组降压幅度更显著（P＜0．05）；对照组hs-CRP、α1-AAG水平明显高于健康者（P＜0．05），治疗组在给予奥美沙坦酯治疗后hs-CRP、α1-AAG水平较对照组明显下降，差异有统计学意义（P＜0．05）。结论奥美沙坦酯联合苯磺酸氨氯地平可以显著降低MHD高血压患者的血压，并可改善MHD患者的微炎症状态，值得推广。Objective To investigate the efficacy of benzene sulfonic acid amlodipine combined with Olmesartan medoxomil on blood pressure and micro -inflammation state in maintenance hemodialysis patients with hypertension . Methods 80 maintenance hemodialysis patients with hypertension were randomly divided into control group and treat -ment group using random number table （ n=40 each ） .The contuol group received oral benzene sulfonic acid amlodip-ine, while treatment group was given oral benzene sulfonic acid amlodipine combined with olmesartan medoxomil .The course of treatment in the two groups was 8 weeks.The changes of blood pressure , high-sensitivity C-reactive protein （ hs-CRP） and α1-acid glycoprotein （α1-AAG） were observed before and after treatment between the two groups . In addition , 40 normal individuals as the healthy control subjects .Results The total effective rate of treatment groups was 90.5%, which was higher than 67.5%of control groups （P〈0.05）.After treatment, both systolic blood pressure and diastolic blood preassure in the two groups was significantly decreased than before treatment （P〈0.05）, while the decompression range of blood pressure in the treatment group was significantly greater than that in the control group （ P〈0.05）;compared with healthy people , hs-CRP and α1-AAG were elevated significantly with maintenance hemodialy-sis patients （P〈0.05）.The level of hs-CRP and α1-AAG were decreased in maintenance hemodialysis patient with taking Olmesartan medoxomil in treatment group .Conclusion Olmesartan medoxomil combined with Benzene Sulfonic Acid Amlodipine can obviously decrease the blood pressure in the maintenance hemodialysis patients with hypenension , and relieve the micro-inflammation state in maintenance hemodialysis patients , is worth promoting the application .

关 键 词：奥美沙坦酯 苯磺酸氨氯地平 维持性血液透析 高血压 微炎症状态 

分 类 号：R544.1[医药卫生—心血管疾病]